BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 27235476)

  • 1. Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation.
    Shetzer Y; Molchadsky A; Rotter V
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27235476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers.
    Solomon H; Dinowitz N; Pateras IS; Cooks T; Shetzer Y; Molchadsky A; Charni M; Rabani S; Koifman G; Tarcic O; Porat Z; Kogan-Sakin I; Goldfinger N; Oren M; Harris CC; Gorgoulis VG; Rotter V
    Oncogene; 2018 Mar; 37(12):1669-1684. PubMed ID: 29343849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Mutant p53-Dependent Embryonic Stem Cell Gene Signature Is Associated with Augmented Tumorigenesis of Stem Cells.
    Koifman G; Shetzer Y; Eizenberger S; Solomon H; Rotkopf R; Molchadsky A; Lonetto G; Goldfinger N; Rotter V
    Cancer Res; 2018 Oct; 78(20):5833-5847. PubMed ID: 30154152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1.
    Loizou E; Banito A; Livshits G; Ho YJ; Koche RP; Sánchez-Rivera FJ; Mayle A; Chen CC; Kinalis S; Bagger FO; Kastenhuber ER; Durham BH; Lowe SW
    Cancer Discov; 2019 Jul; 9(7):962-979. PubMed ID: 31068365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis.
    Stein Y; Rotter V; Aloni-Grinstein R
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
    Di Fiore R; Marcatti M; Drago-Ferrante R; D'Anneo A; Giuliano M; Carlisi D; De Blasio A; Querques F; Pastore L; Tesoriere G; Vento R
    Bone; 2014 Mar; 60():198-212. PubMed ID: 24373920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The paradigm of mutant p53-expressing cancer stem cells and drug resistance.
    Shetzer Y; Solomon H; Koifman G; Molchadsky A; Horesh S; Rotter V
    Carcinogenesis; 2014 Jun; 35(6):1196-208. PubMed ID: 24658181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes.
    Redman-Rivera LN; Shaver TM; Jin H; Marshall CB; Schafer JM; Sheng Q; Hongo RA; Beckermann KE; Wheeler FC; Lehmann BD; Pietenpol JA
    Nat Commun; 2021 Aug; 12(1):5184. PubMed ID: 34465782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
    Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
    Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gain-of-function mutant p53 in cancer progression and therapy.
    Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
    J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells.
    Cordani M; Butera G; Pacchiana R; Masetto F; Mullappilly N; Riganti C; Donadelli M
    Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
    Stiewe T; Haran TE
    Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
    Blandino G; Di Agostino S
    J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gain of Function (GOF) Mutant p53 in Cancer-Current Therapeutic Approaches.
    Roszkowska KA; Piecuch A; Sady M; Gajewski Z; Flis S
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells.
    Vaughan CA; Singh S; Grossman SR; Windle B; Deb SP; Deb S
    Mol Oncol; 2017 Jun; 11(6):696-711. PubMed ID: 28423230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant p53 partners in crime.
    Kim MP; Lozano G
    Cell Death Differ; 2018 Jan; 25(1):161-168. PubMed ID: 29099488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression.
    Yue X; Zhang C; Zhao Y; Liu J; Lin AW; Tan VM; Drake JM; Liu L; Boateng MN; Li J; Feng Z; Hu W
    Genes Dev; 2017 Aug; 31(16):1641-1654. PubMed ID: 28947497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant p53-a potential player in shaping the tumor-stroma crosstalk.
    Stein Y; Aloni-Grinstein R; Rotter V
    J Mol Cell Biol; 2019 Jul; 11(7):600-604. PubMed ID: 31318969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 and its mutants on the slippery road from stemness to carcinogenesis.
    Molchadsky A; Rotter V
    Carcinogenesis; 2017 Apr; 38(4):347-358. PubMed ID: 28334334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chaperoning the guardian of the genome. The two-faced role of molecular chaperones in p53 tumor suppressor action.
    Wawrzynow B; Zylicz A; Zylicz M
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):161-174. PubMed ID: 29355591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.